Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction
Luke Grundy, … , Inmaculada Silos-Santiago, Stuart M. Brierley
Luke Grundy, … , Inmaculada Silos-Santiago, Stuart M. Brierley
Published October 4, 2018
Citation Information: JCI Insight. 2018;3(19):e121841. https://doi.org/10.1172/jci.insight.121841.
View: Text | PDF
Research Article Gastroenterology Neuroscience

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

  • Text
  • PDF
Abstract

Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.

Authors

Luke Grundy, Andrea M. Harrington, Joel Castro, Sonia Garcia-Caraballo, Annemie Deiteren, Jessica Maddern, Grigori Y. Rychkov, Pei Ge, Stefanie Peters, Robert Feil, Paul Miller, Andre Ghetti, Gerhard Hannig, Caroline B. Kurtz, Inmaculada Silos-Santiago, Stuart M. Brierley

×

Figure 9

Colon- and bladder-innervating dorsal root ganglion neurons are largely distinct but their central terminals are closely apposed within the spinal cord.

Options: View larger image (or click on image) Download as PowerPoint
Colon- and bladder-innervating dorsal root ganglion neurons are largely ...
Retrograde tracer from colon- (CTB-555; magenta), bladder- (CTB-488; blue), or dual-traced (white) neurons in CLARITY cleared TL (L1) and LS (L6) dorsal root ganglia (DRG) from (A) control and (B) CVH mice. Scale bar: 100 μm. (C and D) Quantitative data of the number of colon-only, bladder-only, or dual-traced neurons per ganglia within (C) L1 and (D) L6 DRG (N = 3–5 mice per group). Data indicate no significant difference in the total number of colon-only, bladder-only (P = 0.058, unpaired t test), or dual-traced populations of neurons in control and CVH states. (E and F) Quantitative data of dual-traced neurons, expressed as a percentage of colon-innervating neurons in (E) L1 and (F) L6 DRG. Data indicate no significant difference between control and CVH. (G and H) Spinal cord (50-μm sections) showing retrograde tracer from the colon (magenta) or bladder (blue). Imaging reveals that the central terminals of colon-innervating or bladder-innervating DRG neurons are in close apposition to one another within the dorsal horn, including within the lateral spinal nucleus and the lumbar dorsal column (repeated in N = 3 mice). Scale bar: 100 μm. (I and J) Enlarged images from insets within H. Scale bar: 30 μm. (K) Diagrams detailing changes in colon- and bladder-innervating sensory pathways during CVH and (L) how chronic linaclotide treatment normalizes colonic nociception and, subsequently, normalizes bladder afferent function and voiding. Data represent mean ± SEM. P values are based on unpaired t tests (C–F).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts